The partner of health industries and professions
OUR News
Health products pricing : clarification of the “industrial criterion”
PLFSS: medical devices soon to be substitutable by pharmacists
PLFSS: Creation of a specific financing method for advanced therapy medicinal products
PLFSS: New rebates for manufacturers who apply for reimbursement in a limited number of indications
Biosimilars: the Council of State clarifies the notion of prescription efficiency
Real life studies: call for census from the HAS
RECEIVE OUR NEWSLETTER
Our team
Marine devulder
She is mainly involved in issues related to market access for health products, their advertising and relations between health industries and professionals, in which she has developed a strong expertise.
For more information
our interventions
In partnership with
For the health Commission
New reimbursement
models
- Early access
- Compassionate access
- Direct access
Compliance
- The « anti-gift » act
- The « transparency » act
Price
- LEEM / CEPS framework agreement
Other news
- Social security financing bill / Social security financing act
- Regulation « Covid-19 »
SOME DECISIONS
CONSTITUTIONal council
Limitation of the scope of the “safeguard clause” for medical devices
Decision n°2019-795 DC of 20 December 2019,
Social Security Financing Act for 2020
CoUNSIL OF STATE
Cancellation of prescription restrictions accompanying a treatment order
Judgment of 24 February 2020, req. n°431889 and judgment of 8 November 2019, req. n°423971
CourT OF CASSATION
Exclusion from the basis of the tax on expenditure on the promotion of medicines of compensation for notice not served
Judgment of 18 June 2015, appeal no. 14-189661
CourT OF JUSTICE OF THE EUROPEAN UNION
Definition of the conditions under which prescription support software must be qualified as a medical device
Judgment of 7 December 2017, Case C-329-16